Table 6. Univariate and multivariate analyses of prognostic factors for BCSS and DFS of patients with IBC in the entire cohort.
| Variable | BCSS | DFS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||||
| Age at diagnosis, years | |||||||||||
| <40 | Ref | Ref | Ref | Ref | |||||||
| 40–59 | 1.081 (0.588–1.985) | 0.802 | 0.651 (0.213–1.994) | 0.452 | 0.646 (0.428–0.974) | 0.037 | 0.412 (0.228–0.745) | 0.003 | |||
| ≥60 | 0.933 (0.439–1.986) | 0.858 | 0.246 (0.040–1.511) | 0.130 | 0.589 (0.342–1.014) | 0.056 | 0.488 (0.201–1.181) | 0.111 | |||
| Histologic grade | |||||||||||
| 1 vs. 2/3 | 23.164 (0.771–696.039) | 0.070 | 459.991 (0–5.726E+16) | 0.711 | 1.588 (0.777–3.247) | 0.205 | 1.355 (0.462–3.975) | 0.581 | |||
| Molecular subtypes | |||||||||||
| Luminal A-like | Ref | Ref | Ref | Ref | |||||||
| Luminal B-like | 3.601 (1.844–7.031) | <0.001 | 15.101 (1.989–114.668) | 0.009 | 1.856 (1.212–2.843) | 0.004 | 1.712 (0.949–3.092) | 0.074 | |||
| HER2 overexpression | 2.828 (1.138–7.032) | 0.025 | 3.276 (0–8.088E+85) | 0.991 | 1.053 (0.504–2.200) | 0.891 | 0 (0–1.055E+59) | 0.893 | |||
| Basal-like | 1.952 (0.809–4.711) | 0.137 | 4.436 (0–1.095E+86) | 0.988 | 1.192 (0.656–2.166) | 0.564 | 0 (0–2.017E+59) | 0.900 | |||
| Pathological stages | |||||||||||
| I-II vs. III-IV | 5.434 (3.484–8.475) | <0.001 | 4.160 (2.912–5.944) | <0.001 | |||||||
| T stages | |||||||||||
| Tmic | Ref | Ref | Ref | Ref | |||||||
| T1 | 2702.949 (0–9.457E+43) | 0.868 | 1031.937 (0–1.520E+40) | 0.874 | 0.856 (0.268–2.737) | 0.793 | 6672.385 (0–1.571E+67) | 0.906 | |||
| T2 | 6615.571 (0–2.314E+44) | 0.853 | 1815.339 (0–2.678E+40) | 0.864 | 1.522 (0.478–4.849) | 0.477 | 12646.815 (0–2.979E+67) | 0.899 | |||
| T3/T4 | 16128.032 (0–5.651E+44) | 0.839 | 5876.859 (0–8.730E+40) | 0.842 | 3.245 (0.905–11.635) | 0.071 | 24890.946 (0–5.879E+67) | 0.892 | |||
| N stages | |||||||||||
| N0 | Ref | Ref | Ref | Ref | |||||||
| N1 | 2.478 (1.371–4.477) | 0.003 | 4.545 (1.314–15.713) | 0.017 | 1.787 (1.150–2.777) | 0.010 | 1.925 (0.964–3.843) | 0.063 | |||
| N2 | 5.701 (3.154–10.303) | <0.001 | 11.842 (2.831–49.538) | 0.001 | 4.051 (2.579–6.362) | <0.001 | 2.435 (1.011–5.868) | 0.047 | |||
| N3 | 11.102 (5.873–20.985) | <0.001 | 9.167 (1.572–53.449) | 0.014 | 6.338 (3.641–11.034) | <0.001 | 2.166 (0.685–6.844) | 0.188 | |||
| Surgery type | |||||||||||
| BCS vs. MT | 3.194 (1.642–6.210) | 0.001 | 1.057 (0.332–3.363) | 0.925 | 1.335 (0.903–1.974) | 0.147 | 1.572 (0.785–3.145) | 0.202 | |||
| Nodal surgery | |||||||||||
| SLNB | Ref | Ref | Ref | Ref | |||||||
| ALND | 1.938 (0.842–4.462) | 0.120 | 0.424 (0.099–1.817) | 0.248 | 1.032 (0.627–1.698) | 0.902 | 0.470 (0.230–0.960) | 0.038 | |||
| None | 1.266 (0.152–10.519) | 0.827 | 0.001 (0–6.466E+137) | 0.965 | 0.408 (0.054–3.058) | 0.383 | 0 (0–9.177E+212) | 0.970 | |||
| Chemotherapy | |||||||||||
| No vs. yes | 1.852 (0.905–3.789) | 0.092 | 0.499 (0.116–2.158) | 0.352 | 1.672 (1.040–2.688) | 0.034 | 0.674 (0.289–1.572) | 0.361 | |||
| Radiotherapy | |||||||||||
| No vs. yes | 1.504 (0.815–2.774) | 0.192 | 0.320 (0.095–1.072) | 0.065 | 2.297 (1.546–3.413) | <0.001 | 1.517 (0.745–3.091) | 0.251 | |||
| Endocrine therapy | |||||||||||
| No vs. yes | 1.833 (0.812–4.138) | 0.145 | 1.620 (0–3.950E+85) | 0.996 | 2.282 (1.380–3.774) | 0.001 | 0 (0–2.869E+59) | 0.904 | |||
BCSS, breast cancer-specific survival; DFS, disease-free survival; IBC, invasive breast cancer; BCS, breast-conserving surgery; MT, mastectomy; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; Ref, reference group.